Duchenne Muscular Dystrophy Drugs Global Market Report 2026
상품코드:1938650
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
듀셴형 근이영양증 치료제 시장 규모는 최근 급속히 확대하고 있습니다. 2025년 32억 달러에서 2026년에는 36억 4,000만 달러로, CAGR 13.5%로 성장이 전망되고 있습니다. 지난 수년간의 성장 요인으로는 치료 옵션이 제한적인 상황, DMD에 대한 인식 개선, 소아 환자 수 증가, 코르티코스테로이드의 채택, 유전자 치료의 초기 단계 연구개발 등을 꼽을 수 있습니다.
듀셴형 근이영양증 치료제 시장 규모는 향후 수년간 급성장이 전망됩니다. 2030년에는 60억 1,000만 달러에 달하며, CAGR은 13.4%에 달할 전망입니다. 예측 기간 중의 성장은 엑손 스키핑 치료제의 발전, 유전자 편집 기술의 혁신, 정부 및 규제 당국의 지원 강화, 희귀질환 치료에 대한 투자 증가, 전문 의료 및 병원 네트워크의 확대에 기인할 것으로 보입니다. 예측 기간 중 주요 동향으로는 엑손 스키핑 요법의 도입 증가, DMD에 대한 유전자 치료 접근법의 사용 확대, 주사제 및 표적 약물전달 방법의 선호도 증가, 온라인 및 병원 약국 유통 채널의 확대, 미오스타틴 억제제 및 우토로핀 조절제 등 지지요법의 개발 등이 있습니다. 치료제 개발 등을 들 수 있습니다.
맞춤형 의료의 확대는 향후 수년간 뒤쉔형 근이영양증(DMD) 치료제 시장의 성장을 촉진할 것으로 예측됩니다. 맞춤형 의료는 환자 개개인의 유전적 구성, 환경적 영향, 생활습관 요인에 따라 치료법을 맞춤화하여 더 나은 임상결과를 달성하기 위한 헬스케어 접근법입니다. 맞춤형 의료의 보급 확대는 주로 유전체 기술의 발전에 의해 추진되고 있습니다. 이 기술을 통해 유전자 변이의 정확한 식별과 개인별 맞춤 치료법 개발이 가능합니다. 뒤쉔 근이영양증의 경우, 맞춤의료는 특정 유전자 변이에 대한 표적 치료법 개발을 지원하여 약물의 효과와 환자 치료의 전반적인 개선에 기여할 수 있습니다. 또한 돌연변이 특이적 치료에 집중함으로써 약물 개발을 촉진하고 치료 결과를 개선할 수 있습니다. 예를 들어 미국 비영리단체인 맞춤형 의료연합(PMC)에 따르면 2024년 2월 현재 미국 식품의약국(FDA)은 2023년 26건의 새로운 맞춤형 의료 제품을 승인했습니다. 이는 2022년 12건에서 눈에 띄게 증가한 수치입니다. 따라서 맞춤의료의 성장은 뒤쉔형 근이영양증 치료제 시장의 확대에 기여하고 있습니다.
Duchenne 근이영양증 치료제 시장에서 사업을 운영하고 있는 주요 기업은 근력 향상, 질병 진행 지연, 전체 환자 치료 결과 개선을 목표로 하는 코르티코스테로이드 등 혁신적인 치료법 개발에 주력하고 있습니다. 코르티코스테로이드는 부신에서 자연적으로 생성되거나 합성되는 스테로이드계 약물로, 염증 감소와 면역 반응 조절에 효과를 발휘합니다. 예를 들어 2024년 3월에는 미국 바이오 제약기업인 카탈리스트 파마슈티컬스(Catalyst Pharmaceuticals)가 2세 이상의 Duchenne 근이영양증 환자를 위한 치료제로 FDA 승인을 받은 경구용 현탁액 'AGAMREE(바몰로론) 40mg/mL'을 출시했습니다. 출시했습니다. AGAMREE는 염증을 감소시키고 근세포막을 안정화시키는 코르티코스테로이드이며, 이를 통해 질환의 진행을 늦추는 효과를 기대할 수 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 용도 산업의 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의에 의한 공급망에 대한 영향, Covid가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장의 세계 TAM(Total Addressable Market)
제9장 시장 세분화
제10장 지역별·국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 대기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 합병과 인수
제40장 시장의 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSA
영문 목차
영문목차
Duchenne muscular dystrophy (DMD) drugs are medications and therapies designed to manage and slow the progression of Duchenne muscular dystrophy, a genetic disorder that leads to muscle weakness and degeneration. These drugs target the underlying genetic mutations, improve muscle function, and enhance quality of life. The primary goal of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in individuals with DMD.
The main types of drugs in the duchenne muscular dystrophy market include exon skipping drugs, corticosteroids, gene therapy, and other treatments. Exon skipping drugs are specialized therapies that enable the body to produce a functional, albeit shorter, version of the dystrophin protein by bypassing defective sections of the dystrophin gene during protein synthesis. These drugs are administered through oral and injectable routes, and they are distributed via several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have influenced the duchenne muscular dystrophy drugs market by increasing the cost of imported gene therapies, exon skipping drugs, and corticosteroids, which has led to higher treatment costs. Hospital pharmacies and specialty drug segments in regions like North America and Europe are particularly affected due to reliance on imported therapies. While tariffs may temporarily limit accessibility and slow market growth, they also promote local manufacturing initiatives and encourage the development of cost-effective domestic therapies, supporting long-term market resilience.
The duchenne muscular dystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy drugs market statistics, including duchenne muscular dystrophy drugs industry global market size, regional shares, competitors with a duchenne muscular dystrophy drugs market share, detailed duchenne muscular dystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy drugs industry. This duchenne muscular dystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The duchenne muscular dystrophy drugs market size has grown rapidly in recent years. It will grow from $3.2 billion in 2025 to $3.64 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to limited treatment options, increasing awareness of dmd, growing pediatric patient population, adoption of corticosteroids, early-stage r&d in gene therapy.
The duchenne muscular dystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in exon skipping drugs, innovations in gene editing technologies, increasing government and regulatory support, rising investment in rare disease therapies, expansion of specialty care and hospital networks. Major trends in the forecast period include rising adoption of exon skipping therapies, increasing use of gene therapy approaches for dmd, growing preference for injectable and targeted drug delivery, expansion of online and hospital pharmacy distribution channels, development of supportive therapies such as myostatin inhibitors and utrophin modulators.
The expansion of personalized medicine is expected to drive the growth of the Duchenne muscular dystrophy (DMD) drugs market in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic makeup, environmental influences, and lifestyle factors to achieve better clinical outcomes. The increasing adoption of personalized medicine is largely driven by advancements in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored therapies. In the context of Duchenne muscular dystrophy, personalized medicine supports the development of targeted treatments aligned with specific genetic mutations, improving drug effectiveness and overall patient care. It also enhances drug development by concentrating on mutation-specific therapies, leading to improved treatment outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a notable rise from 12 approvals in 2022. Therefore, the growth of personalized medicine is contributing to the expansion of the Duchenne muscular dystrophy drugs market.
Major companies operating in the Duchenne muscular dystrophy drugs market are concentrating on the development of innovative treatment options, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance overall patient outcomes. Corticosteroids are steroid-based medications, either naturally produced by the adrenal glands or synthetically manufactured, that help reduce inflammation and regulate immune responses. For instance, in March 2024, Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, an FDA-approved treatment for Duchenne muscular dystrophy in patients aged two years and older. AGAMREE is a corticosteroid that reduces inflammation and stabilizes muscle cell membranes, thereby helping to slow the progression of the disease.
In July 2023, Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company, acquired the exclusive North American license for vamorolone (AGAMREE), a Duchenne muscular dystrophy drug, from Santhera Pharmaceuticals for an undisclosed amount. Through this acquisition, Catalyst Pharmaceuticals aimed to strengthen its Duchenne muscular dystrophy portfolio by offering a safer and more effective treatment option and addressing the growing demand for targeted therapies for DMD patients. Santhera Pharmaceuticals is a Switzerland-based pharmaceutical company focused on developing innovative treatments for Duchenne muscular dystrophy.
Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc, Sanofi S.A, Novartis AG, Italfarmaco S.p.A, Sarepta Therapeutics Inc, PTC Therapeutics Inc, FibroGen Inc, Wave Life Sciences Ltd, Solid Biosciences Inc, NS Pharma, Capricor Therapeutics Inc, Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc, EspeRare Foundation, Cure Rare Disease, Akashi Therapeutics Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Co Ltd, Nippon Shinyaku Co Ltd, Regenxbio Inc, Ultragenyx Pharmaceutical Inc, Dyne Therapeutics Inc, Entrada Therapeutics Inc.
North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the duchenne muscular dystrophy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Duchenne Muscular Dystrophy Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses duchenne muscular dystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for duchenne muscular dystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Exon Skipping Drugs; Corticosteroids; Gene Therapy; Other Drug Types
2) By Route Of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Exon Skipping Drugs: Eteplirsen; Golodirsen; Viltolarsen; Casimersen; Other Exon Skipping Therapies
2) By Corticosteroids: Prednisone; Deflazacort; Other Corticosteroids
3) By Gene Therapy: Micro-dystrophin Gene Therapy; CRISPR/Cas9-Based Gene Editing; Stem Cell-Based Gene Therapy; Other Gene Therapies
4) By Other Drug Types: Utrophin Modulators; Anti-Inflammatory Agents; Antisense Oligonucleotides; Myostatin Inhibitors; Other Supportive Therapies
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.1.5 Biotechnology, Genomics & Precision Medicine
4.2. Major Trends
4.2.1 Rising Adoption Of Exon Skipping Therapies
4.2.2 Increasing Use Of Gene Therapy Approaches For Dmd
4.2.3 Growing Preference For Injectable And Targeted Drug Delivery
4.2.4 Expansion Of Online And Hospital Pharmacy Distribution Channels
4.2.5 Development Of Supportive Therapies Such As Myostatin Inhibitors And Utrophin Modulators
5. Duchenne Muscular Dystrophy Drugs Market Analysis Of End Use Industries
5.1 Hospital Pharmacies
5.2 Retail Pharmacies
5.3 Online Pharmacies
5.4 Specialty Clinics
5.5 Research Institutions
6. Duchenne Muscular Dystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Duchenne Muscular Dystrophy Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Duchenne Muscular Dystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Duchenne Muscular Dystrophy Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Duchenne Muscular Dystrophy Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Duchenne Muscular Dystrophy Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Duchenne Muscular Dystrophy Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.1. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
9.2. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Injectable
9.3. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.4. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
9.5. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Prednisone, Deflazacort, Other Corticosteroids
9.6. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Duchenne Muscular Dystrophy Drugs Market
12.1. China Duchenne Muscular Dystrophy Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Duchenne Muscular Dystrophy Drugs Market
13.1. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Duchenne Muscular Dystrophy Drugs Market
14.1. Japan Duchenne Muscular Dystrophy Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Duchenne Muscular Dystrophy Drugs Market
15.1. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Duchenne Muscular Dystrophy Drugs Market
16.1. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Duchenne Muscular Dystrophy Drugs Market
17.1. South Korea Duchenne Muscular Dystrophy Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Duchenne Muscular Dystrophy Drugs Market
19.1. South East Asia Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Duchenne Muscular Dystrophy Drugs Market
20.1. Western Europe Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Duchenne Muscular Dystrophy Drugs Market
21.1. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Duchenne Muscular Dystrophy Drugs Market
23.1. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24.1. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25.1. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Duchenne Muscular Dystrophy Drugs Market
26.1. Eastern Europe Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Duchenne Muscular Dystrophy Drugs Market
27.1. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Duchenne Muscular Dystrophy Drugs Market
28.1. North America Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Duchenne Muscular Dystrophy Drugs Market
29.1. USA Duchenne Muscular Dystrophy Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Duchenne Muscular Dystrophy Drugs Market
31.1. South America Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Duchenne Muscular Dystrophy Drugs Market
32.1. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Duchenne Muscular Dystrophy Drugs Market
33.1. Middle East Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Duchenne Muscular Dystrophy Drugs Market
34.1. Africa Duchenne Muscular Dystrophy Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Duchenne Muscular Dystrophy Drugs Market Regulatory and Investment Landscape
36. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Company Profiles
